GnRH antag 
Welcome,         Profile    Billing    Logout  
 29 Companies  18 Products   18 Products   65 Diseases   143 Trials   3714 News 


12345678910111213...3738»
  • ||||||||||  Review, Journal:  Experimental and new investigational drugs for the treatment of uterine fibroids. (Pubmed Central) -  Apr 15, 2024   
    Ongoing research on natural compounds, such as vitamin D and epigallocatechin gallate (EGCG), presents emerging options for treating uterine fibroids. This evolving landscape reflects the ongoing efforts to improve therapeutic outcomes for individuals with symptomatic uterine fibroids.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Journal:  Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix. (Pubmed Central) -  Apr 15, 2024   
    This evolving landscape reflects the ongoing efforts to improve therapeutic outcomes for individuals with symptomatic uterine fibroids. The present study revealed that T bounce with cut-off levels of 20?ng/dL is a promising biomarker that predicts OS and CSS for prostate cancer patients treated with degarelix acetate.
  • ||||||||||  metformin / Generic mfg., finasteride / Generic mfg.
    Review, Journal:  Comparative Management Methods for Adolescents With Polycystic Ovarian Syndrome: A Systemic Review. (Pubmed Central) -  Apr 10, 2024   
    Epilatory and surgical measurements are also available; however, they are reserved for when all other methods fail and once adulthood or an appropriate age is reached. Although there are many pharmaceuticals available, it is necessary to evaluate each adolescent with PCOS uniquely and prescribe the appropriate pharmacotherapy regarding their symptoms.
  • ||||||||||  Clinical, Journal:  Micronized natural progesterone (Seidigestan (Pubmed Central) -  Apr 9, 2024   
    P4
    The outcomes of this trial have the potential to inform evidence-based adjustments in the management of ovarian stimulation protocols for oocyte donors. ClinicalTrials.gov, identifier, NCT05954962.
  • ||||||||||  Women with endometriosis: Patient treatment journey using real-world evidence (RWE) () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_162;    
    Hormonal medication was used infrequently; however, con- comitant analgesic medication was frequently used. Newer hormonal medications indicated for the reduction of EM- associated pain may decrease use of concurrent analgesics and potential morbidity associated with chronic use.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Journal:  Effects of Follicle Stimulating Hormone on Energy Balance and Tissue Metabolic Health After Loss of Ovarian Function. (Pubmed Central) -  Mar 27, 2024   
    Female Wistar rats were ovariectomized and given the GnRH antagonist degarelix to suppress FSH production...Additionally, rats administered FSH had reduced liver triglyceride concentration (p<0.001), which correlated with FSH-induced changes at the transcriptomic level. While not appearing to modulate energy balance after loss of ovarian function in rats, FSH may still impart tissue-specific effects in the liver and white adipose tissue that might affect the metabolic health of those organs.
  • ||||||||||  tranexamic acid oral / Generic mfg.
    Review, Journal:  The efficacy of medical management of leiomyoma-associated heavy menstrual bleeding: a mini review. (Pubmed Central) -  Mar 25, 2024   
    Medical management of HMB is the preferred first-line treatment and includes nonsteroidal anti-inflammatory drugs, contraceptive hormones, tranexamic acid, levonorgestrel intrauterine system, gonadotropin-releasing hormone (GnRH) antagonists and antagonists, selective progesterone receptor modulators, selective estrogen receptor modulators, and aromatase inhibitors...Patients may also face financial barriers to GnRH analog therapy. Future studies are required to delineate the nonhormonal treatment options and the long-term management of leiomyoma-associated HMB.
  • ||||||||||  Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
    Journal:  LH supplementation in IVF: human nature, politics, and elephants in the room. (Pubmed Central) -  Mar 22, 2024   
    Individual genetics of the LH receptor gene may also serve to individualize LH needs during stimulation; however, the jury is still out regarding this approach. Individual endocrine and genetics parameters may shed meaningful light on the question of LH supplemental during ovarian stimulation.
  • ||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Cardiovascular Outcomes of Patients with Advanced Prostate Cancer Treated with Leuprolide or Relugolix (304B) -  Mar 12, 2024 - Abstract #AUA2024AUA_3301;    
    Our results demonstrated a previous history of MACE was the most significant variable associated with increased risk of MACE after initiating ADT (OR=9.29, p<0.001). While relugolix usage was not associated with decreased risk of MACE, it should be noted that patients prescribed relugolix tended to be younger, have fewer cardiac comorbidities, and have shorter terms of ADT compared to men prescribed leuprolide.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    IN-VITRO FERTILIZATION INDUCED SEVERE ACUTE KIDNEY INJURY (SAT-213; Exhibition Hall and Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1481;    
    Early therapeutic interventions if not instituted properly could lead to mortality. The management of these patients entails hydration and albumin infusion.
  • ||||||||||  The Clinical and Economic Burden of Woman with Endometriosis (EM) () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2061;    
    Although not curative, surgical procedures were frequently performed, while FDA-approved medications for EM-associated pain were infrequently used. New pharmacologic therapies for EM-associated pain may help reduce the clinical and humanistic burden of this very prevalent illness in women.
  • ||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Clinical, Journal, Metastases:  Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. (Pubmed Central) -  Mar 7, 2024   
    This multicenter post hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in 2 randomized clinical trials (a phase 2 trial of relugolix vs degarelix, and a subset of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radiotherapy and short-term (24 weeks) ADT (n?=?103) from 2014 to 2015 and men receiving radiotherapy and longer-term (48 weeks) ADT (n?=?157) from 2017 to 2019...Patients receiving longer-term ADT received relugolix, 120 mg, orally once daily (360-mg loading dose) or leuprolide acetate injections every 12 weeks for 48 weeks, with up to 90 days of follow-up...The results of these 2 randomized clinical trials suggest that relugolix rapidly achieves sustained castration in patients with localized and advanced prostate cancer receiving radiotherapy. No new safety concerns were identified when relugolix was used with radiotherapy.
  • ||||||||||  How do GnRH antagonists control prostate cancer? (Purple Area, E03) -  Mar 6, 2024 - Abstract #EAU2024EAU_3692;    
    No new safety concerns were identified when relugolix was used with radiotherapy. Sponsored by Ferring
  • ||||||||||  Industry Seminar by Ferring: Maximising ADT in 2024: Concepts and Controversies (Purple Area, E03) -  Mar 6, 2024 - Abstract #EAU2024EAU_3690;    
    Aim: Determining the impact of gonadotropin-releasing hormone (GnRH) antagonists on prostate cancer control Objectives: To discuss the impact of mechanism of action of GnRH analogues on disease control, enabling participants to make informed decisions in selecting ADT for prostate cancer patients 3. Aim: Optimising ADT strategies in addressing LUTS and as neo/adjuvant therapy in patients with prostate cancer undergoing radiotherapy Objectives: To evaluate the role of ADT in patients with lower urinary tract symptoms (LUTS) and discuss current neo/adjuvant ADT strategies in patients with prostate cancer undergoing radiotherapy to enhance participants expertise in addressing LUTS and tailoring neo/adjuvant ADT strategies.
  • ||||||||||  estradiol/norethindrone oral / Generic mfg., norethindrone / Generic mfg.
    Review, Journal, Combination therapy:  Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents. (Pubmed Central) -  Mar 4, 2024   
    Around one third of patients are not responsive to oral contraceptives or progestins due to progesterone resistance...Oral GnRH antagonists, including elagolix, relugolix, and linzagolix allow oral administration, induce dose dependent reduction of estradiol levels, do not cause initial flare up of endometriosis symptoms, and allow the fast return of ovarian function and menstruation after discontinuation...Linzagolix, in a dose of 75 mg/day, can be used alone to treat endometriosis associated pain. For severe pelvic pain and dyspareunia, linzagolix can be used in a high dose of 200 mg/day with hormonal add-back therapy to preserve bone health.
  • ||||||||||  Preclinical, Retrospective data, Journal:  Cumulative live birth rate of in (Pubmed Central) -  Feb 19, 2024   
    The pregnancy outcomes, including implantation rate, clinical pregnancy rate and miscarriage rate, were all comparable. In addition, the number of retrieved oocytes, mature oocytes and viable embryos were similar (all p?>?0.05) between the two groups.
  • ||||||||||  Journal:  Refrigerated storage and cryopreservation of hormonally induced sperm in the threatened frog, Litoria aurea. (Pubmed Central) -  Feb 10, 2024   
    This highlights the importance of considering maternal age, especially in the context of COVID-19, when evaluating the likelihood of successful pregnancy following ART treatments. Our major findings include: (1) high quality sperm were induced with 20 and 40 IU/g bodyweight of (hCG); (2) proportions of live, motile sperm post-thaw, were recovered at higher levels than previously reported for L. aurea (>50%) when preserved with 15% v/v DMSO and 1% w/v sucrose; and (3) spermic urine stored at 5